Medicinal compounds with antiepileptic/anticonvulsant activities

Epilepsia

Volumn 55, Issue 1, 2014, Pages 3-16

  Zhu, Hui Ling ^a   Wan, Jian Bo ^a   Wang, Yi Tao ^a   Li, Bao Cai ^b   Xiang, Cheng ^b   He, Jing ^b   Li, Peng ^a  

^a University of Macau   (Macao)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alkaloids; Epilepsy; Flavonoids; Medicinal plants; Saponins; Terpenoids

Indexed keywords

3 ACETYLACONITINE; ACONITINE; ALKALOID; ANTICONVULSIVE AGENT; APIGENIN; BAICALIN; BERBERINE; BORNEOL; CANNABIDIOL; CARVACROL; CHRYSIN; COUMARIN DERIVATIVE; DITERPENE; DRONABINOL; FLAVONOID; IBOGAINE; ISORHYNCHOPHYLLINE; LAPPACONITINE; MESACONITINE; N DEACETYLLAPPACONITINE; NANTENINE; PIPERINE; PLANT MEDICINAL PRODUCT; RHYNCHOPHYLLINE; RUTOSIDE; SAPONIN; TERPENOID DERIVATIVE; TETRAHYDROPALMATINE; UNINDEXED DRUG; WOGONIN;

ACONITE; ANTICONVULSANT ACTIVITY; CHEMICAL STRUCTURE; CYNANCHUM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; HERBAL MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; NERVE EXCITABILITY; NEUROPROTECTION; NONHUMAN; PENTYLENETETRAZOLE-INDUCED SEIZURE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TONIC SEIZURE; TREATMENT RESPONSE;

ALKALOIDS; EPILEPSY; FLAVONOIDS; MEDICINAL PLANTS; SAPONINS; TERPENOIDS;

ALKALOIDS; ANIMALS; ANTICONVULSANTS; COUMARINS; EPILEPSY; FLAVONOIDS; HUMANS; PHYTOTHERAPY; SAPONINS; SEIZURES; TERPENES;

EID: 84892924852     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12463     Document Type: Review

References (80)

1. Newton CR, Garcia HH,. Epilepsy in poor regions of the world. Lancet 2012; 380: 1193-1201.
2. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010; 51: 883-890.
3. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
4. Sørensen AT, Kokaia M,. Novel approaches to epilepsy treatment. Epilepsia 2013; 54: 1-10.
5. Chauhan AK, Dobhal MP, Joshi BC,. A review of medicinal plants showing anticonvulsant activity. J Ethnopharmacol 1988; 22: 11-23.
6. Nsour WM, Lau CBS, Wong ICK,. Review on phytotherapy in epilepsy. Seizure 2000; 9: 96-107.
7. Adams M, Schneider SV, Kluge M, et al. Epilepsy in the Renaissance: a survey of remedies from 16th and 17th century German herbals. J Ethnopharmacol 2012; 143: 1-13.
8. Tagarelli G, Tagarelli A, Liguori M, et al. Treating epilepsy in Italy between XIX and XX century. J Ethnopharmacol 2013; 145: 608-613.
9. Cao J, Fan YP,. Experiment research articles overview about single traditional Chinese medicine with anti-epilepsy function. Chin J Basic Med Tradit Chin Med 2006; 12: 875-878.
10. Moshi MJ, Kagashe GA, Mbwambo ZH,. Plants used to treat epilepsy by Tanzanian traditional healers. J Ethnopharmacol 2005; 97: 327-336.
11. Ameri A,. Inhibition of rat hippocampal excitability by the Aconitum alkaloid, 1-benzoylnapelline, but not by napelline. Eur J Pharmacol 1997a; 335: 145-152.
12. Ameri A,. Inhibition of rat hippocampal excitability by the plant alkaloid 3-acetylaconitine mediated by interaction with voltage-dependent sodium channels. Naunyn Schmiedebergs Arch Pharmacol 1997b; 355: 273-280.
13. Ameri A,. Structure-dependent differences in the effects of the Aconitum alkaloids lappaconitine, N-desacetyllappaconitine and lappaconidine in rat hippocampal slices. Brain Res 1997c; 769: 36-43.
14. Ameri A,. Effects of the alkaloids 6-benzoylheteratisine and heteratisine on neuronal activity in rat hippocampal slices. Neuropharmacology 1997d; 36: 1039-1046.
15. Ameri A,. The effects of Aconitum alkaloids on the central nervous system. Prog Neurobiol 1998a; 56: 211-235.
16. Ameri A,. Structure-dependent inhibitory action of the Aconitum alkaloids 14-benzoyltalitasamine and talitasamine in rat hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1998b; 357: 585-592.
17. Ameri A, Gleitz J, Peters T,. Aconitine inhibits epileptiform activity in rat hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1996a; 354: 80-85.
18. Ameri A, Metzmeier P, Peters T,. Frequency-dependent inhibition of neuronal activity by lappaconitine in normal and epileptic hippocampal slices. Br J Pharmacol 1996b; 118: 577-584.
19. Voss LJ, Voss JM, McLeay L, et al. Aconitine induces prolonged seizure-like events in rat neocortical brain slices. Eur J Pharmacol 2008; 584: 291-296.
20. Bhutada P, Mundhada Y, Bansod K, et al. Anticonvulsant activity of berberine, an isoquinoline alkaloid in mice. Epilepsy Behav 2010; 18: 207-210.
21. da Silva AFS, de Andrade JP, Bevilaqua LRM, et al. Anxiolytic-, antidepressant- and anticonvulsant-like effects of the alkaloid montanine isolated from Hippeastrum vittatum. Pharmacol Biochem Behav 2006; 85: 148-154.
22. Lin MT, Wang JJ, Young MS,. The protective effect of dl- tetrahydropalmatine against the development of amygdala kindling seizures in rats. Neurosci Lett 2002; 320: 113-116.
23. Chen K, Kokate TG, Donevan SD, et al. Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology 1996; 35: 423-431.
24. da Cruz GM, Felipe CF, Scorza FA, et al. Piperine decreases pilocarpine-induced convulsions by GABAergic mechanisms. Pharmacol Biochem Behav 2013; 104: 144-153.
25. Felipe FCB, Sousa JT, Souza LEDO, et al. Piplartine, an amide alkaloid from Piper tuberculatum, presents anxiolytic and antidepressant effects in mice. Phytomedicine 2007; 14: 605-612.
26. Kang TH, Murakami Y, Matsumoto K, et al. Rhynchophylline and isorhynchophylline inhibit NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 2002; 455: 27-34.
27. Ribeiro RA, Leite JR,. Nantenine alkaloid presents anticonvulsant effect on two classical animal models. Phytomedicine 2003; 10: 563-568.
28. Rosa DS, Faggion SA, Gavin AS, et al. Erysothrine, an alkaloid extracted from flowers of Erythrina mulungu Mart. ex Benth: evaluating its anticonvulsant and anxiolytic potential. Epilepsy Behav 2012; 23: 205-212.
29. Faggion SA, Cunha AO, Fachim HA, et al. Anticonvulsant profile of the alkaloids (+)-erythravine and (+)-11-alpha-hydroxy-erythravine isolated from the flowers of Erythrina mulungu Mart ex Benth (Leguminosae-Papilionaceae). Epilepsy Behav 2011; 20: 441-446.
30. Charveron M, Assie MB, Stenger A, et al. Benzodiazepine agonist-type activity of raubasine, a rauwolfia serpentina alkaloid. Eur J Pharmacol 1984; 106: 313-317.
31. Medina JH, Paladini AC, Wolfman C, et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 1990; 40: 2227-2231.
32. Avallone R, Zanoli P, Puia G, et al. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem Pharmacol 2000; 59: 1387-1394.
33. Park HG, Yoon SY, Choi JY, et al. Anticonvulsant effect of wogonin isolated from Scutellaria baicalensis. Eur J Pharmacol 2007; 574: 112-119.
34. Raygude KS, Kandhare AD, Ghosh P, et al. Anticonvulsant effect of fisetin by modulation of endogenous biomarkers. Biomed Prev Nutr 2012; 2: 215-222.
35. Liu YF, Gao F, Li XW, et al. The anticonvulsant and neuroprotective effects of baicalin on pilocarpine-induced epileptic model in rats. Neurochem Res 2012; 37: 1670-1680.
36. Abbasi E, Nassiri-Asl M, Shafeei M, et al. Neuroprotective effects of vitexin, a flavonoid, on pentylenetetrazole-induced seizure in rats. Chem Biol Drug Des 2012; 80: 274-278.
37. Nassiri-Asl M, Shariati-Rad S, Zamansoltani F,. Anticonvulsive effects of intracerebroventricular administration of rutin in rats. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 989-993.
38. Nassiri-Asl M, Mortazavi SR, Samiee-Rad F, et al. The effects of rutin on the development of pentylenetetrazole kindling and memory retrieval in rats. Epilepsy Behav 2010; 18: 50-53.
39. de Sousa DP, Goncalves JCR, Quintans L, et al. Study of anticonvulsant effect of citronellol, a monoterpene alcohol, in rodents. Neurosci Lett 2006; 401: 231-235.
40. de Sousa DP, de Farias Nõbrega FF, de Almeida RN,. Influence of the chirality of (R)-(-)- and (S)-(+)-carvone in the central nervous system: a comparative study. Chirality 2007a; 19: 264-268.
41. de Sousa DP, Quintans L, de Almeida RN,. Evolution of the anticonvulsant activity of alfa-terpineol. Pharm Biol 2007b; 45: 69-70.
42. de Almeida RN, de Sousa DP, Nõbrega FFF, et al. Anticonvulsant effect of a natural compound alpha, beta-epoxy-carvone and its action on the nerve excitability. Neurosci Lett 2008; 443: 51-55.
43. de Sousa DP, Nõbrega FFF, Santos CCMP, et al. Anticonvulsant activity of the linalool enantiomers and racemate: investigation of chiral influence. Nat Prod Commun 2010; 5: 1847-1851.
44. de Oliveira PA, Lino FL, Cappelari SE, et al. Effects of gamma-decanolactone on seizures induced by PTZ-kindling in mice. Exp Brain Res 2008; 187: 161-166.
45. Silva MI, Silva MA, de Aquino Neto MR, et al. Effects of isopulegol on pentylenetetrazol-induced convulsions in mice: possible involvement of GABAergic system and antioxidant activity. Fitoterapia 2009; 80: 506-513.
46. Hosseinzadeh H, Sadeghnia HR,. Protective effect of safranal on pentylenetetrazol-induced seizures in the rat: involvement of GABAergic and opioids systems. Phytomedicine 2007; 14: 256-262.
47. Hosseinzadeh H, Talebzadeh F,. Anticonvulsant evaluation of safranal and crocin from Crocus sativus in mice. Fitoterapia 2005; 76: 722-724.
48. Quintans-Júnior LJ, Guimarães AG, Araújo BES, et al. Carvacrol, (-)-borneol and citral reduce convulsant activity in rodents. Afr J Biotechnol 2010; 9: 6566-6572.
49. Huang CW, Chow JC, Tsai JJ, et al. Characterizing the effects of eugenol on neuronal ionic currents and hyperexcitability. Psychopharmacology 2012; 221: 575-587.
50. Costa JP, Ferreira PB, De Sousa DP, et al. Anticonvulsant effect of phytol in a pilocarpine model in mice. Neurosci Lett 2012; 523: 115-118.
51. Talevi A, Cravero MS, Castro EA, et al. Discovery of anticonvulsant activity of abietic acid through application of linear discriminant analysis. Bioorg Med Chem Lett 2007; 17: 1684-1690.
52. McCaughran JA Jr, Corcoran ME, Wada JA,. Anticonvulsant activity of delta-8- and delta-9-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 1974; 2: 227-233.
53. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012; 21: 344-352.
54. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010; 332: 569-577.
55. Wallace MJ, Wiley JL, Martin BR, et al. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001; 428: 51-57.
56. Pertwee RG,. Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol. Euphytica 2004; 140: 73-82.
57. Taviano MF, Miceli N, Monforte MT, et al. Ursolic acid plays a role in Nepeta sibthorpii bentham CNS depressing effects. Phytother Res 2007; 21: 382-385.
58. Kazmi I, Gupta G, Afzal M, et al. Anticonvulsant and depressant-like activity of ursolic acid stearoyl glucoside isolated from Lantana camara L. (verbanaceae). Asian Pac J Cancer Prev 2012; 2: S453-S456.
59. Yu YH, Xie W, Bao Y, et al. Saikosaponin a mediates the anticonvulsant properties in the HNC models of AE and SE by inhibiting NMDA receptor current and persistent sodium current. PLoS ONE 2012; 7: e50694.
60. Pandey R, Gupta S, Tandon S, et al. Baccoside A suppresses epileptic-like seizure/convulsion in Caenorhabditis elegans. Seizure 2010; 19: 439-442.
61. Sasaki K, Hatta S, Haga M, et al. Effects of bilobalide on γ-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol 1999; 367: 165-173.
62. Sasaki K, Hatta S, Wada K, et al. Bilobalide prevents reduction of gamma-aminobutyric acid levels and glutamic acid decarboxylase activity induced by 4-O-methylpyridoxine in mouse hippocampus. Life Sci 2000; 67: 709-715.
63. Mu QZ, Lu JR, Zhou QL,. Two new antiepilepsy compounds-otophyllosides A and B. Sci Sin B 1986; 29: 295-301.
64. Zhou J,. Bioactive glycosides from Chinese medicines. Mem Inst Oswaldo Cruz 1991; 86: 231-234.
65. Lian XY, Zhang TZ, Stringer JL,. Anticonvulsant activity of ginseng on seizures induced by chemical convulsants. Epilepsia 2005; 46: 15-22.
66. Jalsrai A, Grecksch G, Becker A,. Evaluation of the effects of Astragalus mongholicus Bunge saponin extract on central nervous system functions. J Ethnopharmacol 2010; 131: 544-549.
67. Chindo BA, Anuka JA, McNeil L, et al. Anticonvulsant properties of saponins from Ficus platyphylla stem bark. Brain Res Bull 2009; 78: 276-282.
68. Woo TS, Yoon SY, dela Peña IC, et al. Anticonvulsant effect of Artemisia capillaris Herba in mice. Biomol Ther 2011; 19: 342-347.
69. Luszczki JJ, Glowniak K, Czuczwar SJ,. Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res 2007; 59: 18-22.
70. Luszczki JJ, Andres-Mach M, Cisowski W, et al. Osthole suppresses seizures in the mouse maximal electroshock seizure model. Eur J Pharmacol 2009a; 607: 107-109.
71. Luszczki JJ, Wojda E, Andres-Mach M, et al. Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res 2009b; 85: 293-299.
72. Łuszczki JJ, Andres-Mach M, Gleńsk M, et al. Anticonvulsant effects of four linear furanocoumarins, bergapten, imperatorin, oxypeucedanin, and xanthotoxin, in the mouse maximal electroshock-induced seizure model: a comparative study. Pharmacol Rep 2010; 62: 1231-1236.
73. Tosun F, Kizilaya ÇA, Erol K, et al. Anticonvulsant activity of furanocoumarins and the essential oil obtained from the fruits of Heracleum crenatifolium. Food Chem 2008; 107: 990-993.
74. Singhuber J, Baburin I, Ecker GF, et al. Insights into structure-activity relationship of GABAA receptor modulating coumarins and furanocoumarins. Eur J Pharmacol 2011; 668: 57-64.
75. Loscher W,. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002; 50: 105-123.
76. Castel-Branco MM, Alves GL, Figueiredo IV, et al. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find Exp Clin Pharmacol 2009; 31: 101-106.
77. Löscher W, Hönack D, Fassbender CP, et al. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991; 8: 171-189.
78. Cortesi M, Fusar-Poli P,. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Med Hypotheses 2007; 68: 920-921.
79. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175-185.
80. Lorenz R,. On the application of cannabis in paediatrics and epileptology. Neuro Endocrinol Lett 2004; 25: 40-44.